LYB014

**LYB014** is an investigational recombinant protein malaria vaccine from Patronus Biotech that uses the proprietary U-VLP® virus-like-particle platform. It is designed to induce protective humoral and cellular immune responses against *Plasmodium falciparum* across multiple parasite life-cycle stages, with the program described as targeting all three critical stages of the parasite life cycle. The candidate is being evaluated with the low-cost A02 adjuvant system and remains in preclinical/IND-enabling development for malaria prevention. ([prnewswire.com](https://www.prnewswire.com/apac/news-releases/patronus-biotech-receives-grant-to-evaluate-a-novel-malaria-vaccine-and-adjuvant-to-support-affordable-access-and-use-in-global-health-302626605.html))

Other names

Malaria Vaccine疟疾疫苗